BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Caunedo Álvarez Á, Vilches Arenas Á, Argüelles-Arias F. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therap Adv Gastroenterol 2019;12:1756284819858052. [PMID: 31258621 DOI: 10.1177/1756284819858052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Abraham B, Eksteen B, Nedd K, Kale H, Patel D, Stephens J, Shelbaya A, Chambers R, Soonasra A. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Adv Ther 2022;39:2109-27. [PMID: 35296993 DOI: 10.1007/s12325-022-02104-6] [Reference Citation Analysis]
2 Hillhouse E, Mathurin K, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. Adv Ther 2022;39:455-87. [PMID: 34780028 DOI: 10.1007/s12325-021-01951-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Khan N, Patel D, Pernes T, Patel M, Trivedi C, Medvedeva E, Xie D, Yang Y. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2021;3:otab022. [DOI: 10.1093/crocol/otab022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. Biologics 2021;15:1-15. [PMID: 33442230 DOI: 10.2147/BTT.S285610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Queiroz NSF, Saad-Hossne R, FrÓes RSB, Penna FGCE, Gabriel SB, Martins AL, Teixeira FV. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol 2020;57:232-43. [PMID: 32935741 DOI: 10.1590/S0004-2803.202000000-45] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis 2020;26:1498-508. [PMID: 32840322 DOI: 10.1093/ibd/izaa215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf 2020;19:807-16. [PMID: 32441228 DOI: 10.1080/14740338.2020.1773430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Infliximab. Reactions Weekly 2019;1762:214-214. [DOI: 10.1007/s40278-019-64953-7] [Reference Citation Analysis]